Skip to content
ppharmaranks
Menu

Best Peroxisome Proliferator Receptor alpha Agonist for coronary artery disease

Top-rated pick: Gemfibrozil — pharmaranks score 70/100, the highest of the 3 Peroxisome Proliferator Receptor alpha Agonist drugs used for coronary artery disease, ranked by our independent FDA recall-safety score. Compare them with all treatments for coronary artery disease or the full Peroxisome Proliferator Receptor alpha Agonist class. Not medical advice — always consult a professional.

Quick answer: Of the 3 peroxisome proliferator receptor alpha agonist drugs we rate for coronary artery disease, all are available as lower-cost generics, and most are tablet. Our ranking reflects each drug’s FDA recall-safety record — not clinical effectiveness for coronary artery disease; the right choice depends on your situation, so confirm it with your prescriber.

Rated against independent regulatory sources·Last updated August 17, 2026·How we rate

Top peroxisome proliferator receptor alpha agonist for coronary artery disease: 1. Gemfibrozil · 2. Lopid · 3. Lipofen

Best-rated Peroxisome Proliferator Receptor alpha Agonist for coronary artery disease, ranked by pharmaranks score
#DrugRatingPharmacy pays
170/100$3View →
264/100$3View →
3Not yet rated$3View →

Full ranking · 3 drugs

Frequently asked

What is the best peroxisome proliferator receptor alpha agonist for coronary artery disease?
By our independent recall-safety rating — not an efficacy measure — gemfibrozil ranks highest among Peroxisome Proliferator Receptor alpha Agonist drugs used for coronary artery disease. Always consult a professional.
Which peroxisome proliferator receptor alpha agonist drugs treat coronary artery disease?
pharmaranks lists 3 Peroxisome Proliferator Receptor alpha Agonist products used for coronary artery disease, per NIH RxClass drug-classification data — each independently rated and ranked above.
How are these ranked?
By our independent score, currently based on FDA regulatory recall-safety data (the methodology blends additional sources as they come online). See the How we rate page.